Remote Monitoring in Cancer Care: A Platform Study
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Head and Neck Carcinoma
- Sponsor
- Mayo Clinic
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Sensitivity, specificity, positive predictive value and negative predictive value of remote monitoring-based CRS detection/ prediction (Arm 1)
- Status
- Completed
- Last Updated
- 6 months ago
Overview
Brief Summary
This study investigates a device that closely monitors vital signs, as well as a smartphone application (app) that allows patients to respond to different questions and tests that will monitor for new symptoms. This study may help researchers understand if wearing the device is a better tool than standard vital sign assessment tools done only while at the doctor's office or hospital, and if using the smartphone app is a better tool than standard assessment tools used while in the doctor's office or hospital.
Detailed Description
PRIMARY OBJECTIVES: I. Develop patient-specific algorithms to predict the trajectory of cytokine release syndrome (CRS) and or neurotoxicity and time to escalation of medical intervention is needed. (Arm 1) II. Establish the validity for the use of mobile technology to assess neurologic symptoms remotely. (Arm 1) III. Compare the time to escalation of potential medical intervention between remote monitoring (RM) and standard care (SC) based on retrospective analysis of clinical trial data. (Arm 1) IV. Establish the feasibility for the use of wearable device for continuous, remote monitoring of physiologic parameters by quantifying false alerts and downstream clinical actions. (Arm 1) V. Define the range of physiologic variables associated with receipt of radiation and chemotherapy. (Arm 2) VI. Correlate PROs and physician rated CTCAE to biologic parameters. (Arm 2) VII. Establish the feasibility for the use of wearable device for continuous, remote monitoring of physiologic parameters by quantifying false alerts and downstream clinical actions. (Arm 2) OUTLINE: ARM 1: Patients undergoing CAR-T therapy use the Biofourmis wearable device(s) and smartphone app to answer a series of questions about health and neurologic symptoms a few times a day for 5 weeks. ARM 2: Patients undergoing radiation therapy (RT) for head and neck, lung, or gastrointestinal cancers use the Biofourmis wearable device(s) for 60 to 90 days after completion of RT. Patients also use the smartphone app to answer a series of questions about health and neurologic symptoms before start of RT, after completion of RT, 3 months after completion of RT, and 1 year after completion of RT. In addition, patients complete weekly questionnaires regarding side effects and tolerance of the device.
Investigators
Eligibility Criteria
Inclusion Criteria
- •ARM 1: Age \>= 18 years
- •ARM 1: Provide written informed consent
- •ARM 1: Patients undergoing commercial CAR-T cell therapy in an outpatient setting
- •ARM 2: Age \>= 18 years
- •ARM 2: Provide written informed consent
- •ARM 2: Patients with a plan to undergo radiation therapy for lung, gastrointestinal, or head and neck cancer
Exclusion Criteria
- •ARM 1: Non-English speaking
- •ARM 1: Planned initiation of lymphodepleting chemotherapy in the inpatient setting
- •ARM 2: Non-English speaking
Outcomes
Primary Outcomes
Sensitivity, specificity, positive predictive value and negative predictive value of remote monitoring-based CRS detection/ prediction (Arm 1)
Time Frame: Up to 5 weeks
Assessment of neurotoxicity via digital capture of neurological assessment (Arm 1)
Time Frame: Up to 5 weeks
Will assess agreement and concordance between assessment of neurotoxicity via digital capture of neurological assessment (ICE) as compared to standard in-person assessment.
BF-Mayo Neuro test (Arm 1)
Time Frame: Up to 5 weeks
Will assess agreement and concordance between BF-Mayo Neuro test and ICE-based assessment of neurotoxicity.
Sensitivity, specificity, positive predictive value and negative predictive value of novel digital neurotoxicity tests (BF-Neuro) (Arm 1)
Time Frame: Up to 5 weeks
Will compare to standard in-person ICE based neurotoxicity assessment.
Range of physiologic variables associated with receipt of radiation and chemotherapy (Arm 2)
Time Frame: Up to 1 year
Quantification of false alerts and downstream clinical actions (Arm 2)
Time Frame: Up to 1 year
Will be used for the establishment of the feasibility for the use of wearable device for continuous, remote monitoring of physiologic parameters.
Secondary Outcomes
- Biovital index (Arm 1)(Up to 5 weeks)
- Point-in-time assessment of physiological signals from standard of care devices (Arm 1)(Up to 5 weeks)
- BF-Mayo Neuro Test (Arm 1)(Up to 5 weeks)
- Point-in-time assessment of physiological signals from wearable devices (Arm 1)(Up to 5 weeks)